Acorda Therapeutics, Inc. (NASDAQ:ACOR) went down by -0.38% from its latest closing price when compared to the 1-year high value of $4.46 and move down -757.69%, while ACOR stocks collected -0.15% of loss with the last five trading sessions. Press Release reported on 08/04/20 that Acorda Reports Second Quarter 2020 Financial Results
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Worth an Investment?
Acorda Therapeutics, Inc. (NASDAQ: ACOR) The 36 Months beta value for ACOR stocks is at 1.45, while 1 of the analysts out of 5 who provided ratings for Acorda Therapeutics, Inc. stocks as a “buy” while 0 as overweight, 3 rated it as hold and 1 as sell. The average price we get from analysts is $3.00 which is -$0.52 below current price. ACOR currently has a short float of 21.24% and public float of 47.18M with average trading volume of 2.34M shares.
ACOR Market Performance
ACOR stocks went down by -0.15% for the week, with the monthly drop of -18.09% and a quarterly performance of -30.11%, while its annual performance rate touched -82.05%. The simple moving average for the period of the last 20 days is -16.48% for ACOR stocks with the simple moving average of -56.99% for the last 200 days.
Analysts’ Opinion on Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Many brokerage firms have already submitted their reports for ACOR stocks, with H.C. Wainwright repeating the rating for ACOR shares by setting it to “Neutral”. The predicted price for ACOR socks in the upcoming period according to H.C. Wainwright is $6 based on the research report published on August 14, 2019.
Wedbush , on the other hand, stated in their research note that they expect to see ACOR stock at the price of $6. The rating they have provided for ACOR stocks is “Neutral” according to the report published on May 23, 2019.
Goldman gave “ Sell” rating to ACOR stocks, setting the target price at $6 in the report published on December 11, 2018.
ACOR Stocks -23.86% Far from 50 Day Moving Average
After a stumble in the market that brought ACOR to its low price for the period of the last 52 weeks, Acorda Therapeutics, Inc. was unable to take a rebound, for now settling with -88.25% of loss for the given period.
The stock volatility was left at 7.90%, however, within the period of a single month, the volatility rate increased by 7.57%, while the shares sank at the distance of -26.14% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -34.89% lower at the present time.
In the course of the last 5 trading sessions, ACOR went down by -0.15%, which changed the moving average for the period of 200 days to the total of -70.96% of losses for the stock in comparison to the 20-day moving average settled at $0.6184. In addition, Acorda Therapeutics, Inc. saw -74.30% in overturn over the period of a single year with a tendency to cut further losses.
ACOR Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Acorda Therapeutics, Inc. (ACOR), starting from Wasman Jane, who sold 2,227 shares at the price of $1.60 back on Dec 02. After this action, Rushing now owns 117,420 shares of Acorda Therapeutics, Inc., valued at $3,553 with the latest closing price.
Sabella Lauren M, the Chief Commercial Officer of Acorda Therapeutics, Inc., sold 1,513 shares at the value of $1.60 during a trade that took place back on Dec 02, which means that Sabella Lauren M is holding 12,624 shares at the value of $2,421 based on the most recent closing price.
ACOR Stock Fundamentals
The current profitability levels are settled at -60.60 for the present operating margin and +68.56 for gross margin. The net margin for Acorda Therapeutics, Inc. stands at -141.87. Total capital return value is set at -14.84, while invested capital returns managed to touch -35.39. Equity return holds the value -74.60%, with -28.10% for asset returns.
Based on Acorda Therapeutics, Inc. (ACOR), the company’s capital structure generated 88.16 points for debt to equity in total, while total debt to capital is set at the value of 46.85. Total debt to assets is settled at the value of 30.45 with long-term debt to equity ratio rests at -5.33 and long-term debt to capital is 81.99.
The value for Enterprise to Sales is 1.21 with debt to enterprise value settled at 1.18. The receivables turnover for Acorda Therapeutics, Inc. is 8.46 with the total asset turnover at the value of 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.33.